WAYNE, Pa & MISGAV, Israel--(BUSINESS WIRE)--Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company was informed today by Dr. Alastair Clemow, a director of the Company that he purchased 4,500 shares of common stock on the open market on December 16, 2013 at an average price of $5.7787 per share.
Help employers find you! Check out all the jobs and post your resume.
